Predict your next investment

Vertex Pharmaceuticals company logo
Corporation
HEALTHCARE | Medical Facilities & Services / Medical Laboratories & Research
vrtx.com

See what CB Insights has to offer

Investments

7

Partners & Customers

10

About Vertex Pharmaceuticals

Vertex Pharmaceuticals (NASDAQ: VRTX) develops small molecule drugs for serious diseases. The company's strategy is to commercialize its products both independently and in collaboration with major pharmaceutical companies. Vertex's product pipeline is focused on viral diseases, cystic fibrosis, inflammation, autoimmune diseases, cancer, and pain. Vertex co-discovered the HIV protease inhibitor, Lexiva, with GlaxoSmithKline.

Vertex Pharmaceuticals Headquarter Location

50 Northern Avenue

Boston, Massachusetts, 02210,

United States

1-617-341-6100

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Vertex Pharmaceuticals Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Vertex Pharmaceuticals Rank

Research containing Vertex Pharmaceuticals

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Vertex Pharmaceuticals in 3 CB Insights research briefs, most recently on Aug 31, 2021.

Latest Vertex Pharmaceuticals News

The Zacks Analyst Blog Highlights: Vertex Pharma, Amgen, Blueprint Medicines, Deciphera Pharma and CTI BioPharma

Dec 3, 2021

For Immediate Release Chicago, IL – December 3, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Vertex Pharmaceuticals Inc. VRTX , Amgen Inc. AMGN , Blueprint Medicines Corporation BPMC , Deciphera Pharmaceuticals, Inc. DCPH and CTI BioPharma Corp. CTIC . - Zacks Biotech Stock Roundup: Pipeline Updates, Acquisitions & More The biotech sector has been in focus over the past week with acquisition news, label expansion of existing drugs and other regulatory updates. Recap of the Week’s Most Important Stories: Vertex Up on Study Results: Shares of Vertex Pharmaceuticals gained after it announced positive results from a mid-stage study on VX-147. The phase 2 proof-of-concept (POC) study evaluated the efficacy, safety and pharmacokinetics of VX-147 in patients with APOL1-mediated focal segmental glomerulosclerosis (FSGS), a form of chronic kidney disease. Treatment with VX-147 led to a statistically significant, substantial and clinically meaningful mean reduction in proteinuria of 47.6% at 13 weeks compared to baseline and was well tolerated. Based on these positive results, Vertex plans to advance VX-147 into pivotal development in APOL1-mediated kidney disease, including FSGS, in the first quarter of 2022. Pipeline Update from Amgen: Amgen announced positive top-line results from the phase III, multicenter, randomized, placebo-controlled, double-blind study — DISCREET. The study evaluated the efficacy of Otezla (apremilast) in adults with moderate to severe genital psoriasis and moderate to severe plaque psoriasis. Results showed that oral Otezla 30 mg twice daily achieved a clinically meaningful and statistically significant improvement compared with placebo, in the primary endpoint of the modified static Physician's Global Assessment of Genitalia (sPGA-G) response at week 16. In addition, all secondary endpoints were met. Amgen also announced that the FDA has approved the label expansion of the Kyprolis to include its use in combination with Darzalex Faspro and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy. Blueprint to Acquire Lengo Therapeutics:  Blueprint Medicines announced that it will  acquire  Lengo Therapeutics, a privately held precision oncology company, for $250 million in cash. Lengo Therapeutics is also entitled to up to $215 million in milestone payments. The acquisition will add LNG-451, a highly selective brain-penetrant precision therapy targeting EGFR exon 20 insertion mutations, to Blueprint Medicines' lung cancer pipeline. Lengo Therapeutics expects to submit an investigational new drug (IND) application for LNG-451 to the FDA in December 2021. With the addition of LNG-451, Blueprint Medicines will have three investigational compounds that cover the majority of all activating mutations in EGFR, the second most common oncogenic driver in NSCLC. The acquisition is expected to close in the ongoing quarter. Deciphera Gains on Restructuring Program: Shares of Deciphera Pharmaceuticals  gained  following the announcement of a corporate restructuring program whereby the company will prioritize clinical development of select programs, streamline commercial operations, maintain a focus on discovery research and extend its cash runway. The company will reduce its workforce by approximately 35%, or about 140 positions. Deciphera will focus on the clinical development of its vimseltinib and DCC-3116 programs, discontinuing the development of the rebastinib program. Deciphera will continue to commercialize Qinlock for the treatment of fourth-line GIST in the United States with a reduced commercial team. These changes are expected to significantly reduce operating expenses and extend the company’s cash runway into 2024. CTI BioPharma Plunges on Regulatory Update: Shares of CTI BioPharma plunged after the FDA extended the review period for the new drug application (NDA) for pacritinib for the treatment of adult patients with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF) with a baseline platelet count of <50 × 109/L. The target action date has been extended by three months to Feb 28, 2022. Earlier, the FDA granted priority to the NDA for patients with myelofibrosis with a target action date of Nov 30, 2021. However, the FDA requested additional clinical data, which was submitted to the agency on Nov 24, 2021. The FDA informed the company that it considers the data submission to constitute a "major amendment" to the NDA. Therefore, the target action date has been extended by three months to provide additional time for a full submission review. Performance The Nasdaq Biotechnology Index has lost 2.03% in the past four trading sessions. Among the biotech giants, Moderna has gained 12.39% during the period. Over the past six months, shares of Moderna have soared 89.20%. (See the last biotech stock roundup here:  Biotech Stock Roundup: Drug Approvals for BMRN, Updates From BIIB, BMY, MRNA & More ). What's Next in Biotech? Media Contact   Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release. Zacks' Top Picks to Cash in on Artificial Intelligence In 2021, this world-changing technology is projected to generate $327.5 billion in revenue. Now Shark Tank star and billionaire investor Mark Cuban says AI will create "the world's first trillionaires." Zacks' urgent special report reveals 3 AI picks investors need to know about today.

Vertex Pharmaceuticals Investments

7 Investments

Vertex Pharmaceuticals has made 7 investments. Their latest investment was in Arbor Biotechnologies as part of their Series B on November 11, 2021.

CBI Logo

Vertex Pharmaceuticals Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

11/9/2021

Series B

Arbor Biotechnologies

$215M

No

4

10/26/2021

Unattributed

Subscribe to see more

$99M

Subscribe to see more

10

10/26/2021

Convertible Note - III

Subscribe to see more

$99M

Subscribe to see more

10

9/9/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

12/2/2019

Corporate Minority - P2P

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/9/2021

10/26/2021

10/26/2021

9/9/2021

12/2/2019

Round

Series B

Unattributed

Convertible Note - III

Series B

Corporate Minority - P2P

Company

Arbor Biotechnologies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$215M

$99M

$99M

$99M

$99M

New?

No

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

4

10

10

10

10

Vertex Pharmaceuticals Acquisitions

5 Acquisitions

Vertex Pharmaceuticals acquired 5 companies. Their latest acquisition was Semma Therapeutics on September 03, 2019.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

9/3/2019

Series B

$991

$163M

Acquired

6

6/6/2019

Series A

Subscribe to see more

$991

$99M

Subscribe to see more

10

3/24/2017

Subscribe to see more

$991

$99M

Subscribe to see more

10

3/4/2009

Subscribe to see more

$991

$99M

Subscribe to see more

10

7/23/2001

Series A - II

Subscribe to see more

$991

$99M

Subscribe to see more

10

Date

9/3/2019

6/6/2019

3/24/2017

3/4/2009

7/23/2001

Investment Stage

Series B

Series A

Series A - II

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

$991

$991

$991

Total Funding

$163M

$99M

$99M

$99M

$99M

Note

Acquired

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

6

10

10

10

10

Vertex Pharmaceuticals Partners & Customers

10 Partners and customers

Vertex Pharmaceuticals has 10 strategic partners and customers. Vertex Pharmaceuticals recently partnered with Arbor Biotechnologies on August 8, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

8/24/2021

Licensor

Arbor Biotechnologies

United States

Vertex and Arbor Biotechnologies Establish New Partnership to Develop Novel ex vivo Engineered Cell Therapies.

Under this new partnership , Vertex Pharmaceuticals Incorporated will receive rights to use Arbor Biotechnologies 's technology to research and develop ex vivo engineered cell therapies towards Vertex Pharmaceuticals Incorporated 's goal of generating fully differentiated , insulin-producing hypoimmune islet cells for the treatment of type 1 diabetes , for next-generation approaches in sickle cell disease and beta thalassemia , and for the treatment of other diseases .

2

4/22/2021

Licensor

Obsidian Therapeutics

United States

Vertex and Obsidian Therapeutics Establish Collaboration to Discover Novel Therapies That Regulate Gene Editing.

`` This collaboration with Obsidian Therapeutics , Inc. builds upon and will expand Vertex Pharmaceuticals Incorporated 's leadership in small molecule and genetic therapies , and we 're excited to partner with the team at Obsidian Therapeutics , Inc. to explore the capabilities of their technology , '' said Vertex Pharmaceuticals Incorporated 's .

1

4/20/2021

Partner

CRISPR Therapeutics

United States

Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for Development, Manufacturing and Commercialization of CTX001™ in Sickle Cell Disease and Beta Thalassemia | Vertex Pharmaceuticals

`` Our increased investment in our partnership with CRISPR Therapeutics , Inc. is based on the compelling clinical profile of CTX001 , which shows its potential to be a durable cure for patients with SCD and TDT , and the rapid progress that we and our partners at CRISPR Therapeutics , Inc. have made toward registration and commercialization .

3

12/22/2020

Licensor

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

12/22/2020

Licensor

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

8/24/2021

4/22/2021

4/20/2021

12/22/2020

12/22/2020

Type

Licensor

Licensor

Partner

Licensor

Licensor

Business Partner

Arbor Biotechnologies

Obsidian Therapeutics

CRISPR Therapeutics

Country

United States

United States

United States

Subscribe to see more

Subscribe to see more

News Snippet

Vertex and Arbor Biotechnologies Establish New Partnership to Develop Novel ex vivo Engineered Cell Therapies.

Under this new partnership , Vertex Pharmaceuticals Incorporated will receive rights to use Arbor Biotechnologies 's technology to research and develop ex vivo engineered cell therapies towards Vertex Pharmaceuticals Incorporated 's goal of generating fully differentiated , insulin-producing hypoimmune islet cells for the treatment of type 1 diabetes , for next-generation approaches in sickle cell disease and beta thalassemia , and for the treatment of other diseases .

Vertex and Obsidian Therapeutics Establish Collaboration to Discover Novel Therapies That Regulate Gene Editing.

`` This collaboration with Obsidian Therapeutics , Inc. builds upon and will expand Vertex Pharmaceuticals Incorporated 's leadership in small molecule and genetic therapies , and we 're excited to partner with the team at Obsidian Therapeutics , Inc. to explore the capabilities of their technology , '' said Vertex Pharmaceuticals Incorporated 's .

Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for Development, Manufacturing and Commercialization of CTX001™ in Sickle Cell Disease and Beta Thalassemia | Vertex Pharmaceuticals

`` Our increased investment in our partnership with CRISPR Therapeutics , Inc. is based on the compelling clinical profile of CTX001 , which shows its potential to be a durable cure for patients with SCD and TDT , and the rapid progress that we and our partners at CRISPR Therapeutics , Inc. have made toward registration and commercialization .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

1

3

10

10

Vertex Pharmaceuticals Team

34 Team Members

Vertex Pharmaceuticals has 34 team members, including current Chief Executive Officer, President, Reshma Kewalramani MD FASN.

Name

Work History

Title

Status

Reshma Kewalramani MD FASN

Amgen, Brigham Health, Mass General Brigham, and Massachusetts General Hospital

Chief Executive Officer, President

Current

Ashley Grist

Chief Financial Officer

Current

Sazzad Hussain

Chief Revenue Officer

Current

Mei Liu

Chief Revenue Officer

Current

Carmen Bozic MD

Chief Medical Officer

Current

Name

Reshma Kewalramani MD FASN

Ashley Grist

Sazzad Hussain

Mei Liu

Carmen Bozic MD

Work History

Amgen, Brigham Health, Mass General Brigham, and Massachusetts General Hospital

Title

Chief Executive Officer, President

Chief Financial Officer

Chief Revenue Officer

Chief Revenue Officer

Chief Medical Officer

Status

Current

Current

Current

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.